Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $1.3052W HIGH $22.20
Volume
95.12 K
Value Traded
1.03 M
Short % Float
2.03%
Days to Cover
1.5
-2.84%Week
-34.76%1 Month
-53.87%3 Month
-81.58%6 Month
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
11.47 M
EPS (TTM)
-1.41
P/E Ratio
-
Ent. Value
13.55 M
Total Shares
8.38 M
Float Shares
8.09 M
Insiders
3.43%
Institutions
52.37%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | Small Molecule | Oncology | - |
PoA blends historical approval base rates, trial design score and FDA review track record.
FEMY Catalyst Timeline
Dated clinical, regulatory and corporate events for Femasys Inc.
Past FDA Catalysts and PDUFA Decisions
How FEMY actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| - | Example Drug | Phase 3 data readout | Phase 3 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
No drug pipeline
Femasys Inc. is a medical device company. The clinical trials it takes part in test other companies' drugs, so it has no drug pipeline of its own to score.
Clinical Trial Results
Readouts, endpoints and source filings for every FEMY program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| FemaSeed | infertility | 2024-03-20 | 24% of women became pregnant after FemaSeed; 6.7% pregnancy rate noted for traditional IUI methodsRead More | Femasys Announces Positive Topline Data from Pivotal Trial for its FDA-Cleared FemaSeed for the Treatment of Infertility -- In the severe male factor cohort, findings show 24% of women became pregnant after FemaSeed -- -Read More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Mifek Jeffrey GeraldOfficer (Chief Clinical-Medical Affairs) | Buy | 3,125 3,125 held | $3.20 | 08/07/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in FEMY
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| TRI LOCUM PARTNERS LP | 0 % | 29.56 K | 30.61 K |
FEMY Institutional Ownership Trends
FEMY Short Interest
Shares sold short, counted twice a month.
2.03%
Short % of Float
of tradable shares sold short
164.1K
Shares Sold Short
-71.6% vs prior count
1.5 Low
Days to Cover
trading days of normal volume to buy every short share back
108.3K
Avg Daily Volume
the average used for days to cover
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How FEMY ranks across every disease it competes in
Competitive Position is a premium feature
See how FEMY ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialFEMY News
-FEMY
Oct 30, 2026▲ +1.1%today
Femasys Appoints John Moorhead to Board of Directors
Femasys Inc. has appointed John Moorhead to its Board of Directors to enhance its commercialization efforts for the FemaSeed fertility portfolio. Moorhead brings over two decades of experience in marketing and brand development. The company is also advancing its FemBloc product towards FDA approval while having received regulatory approvals in Europe, the UK, and New Zealand.
Read more →-FEMY
Oct 20, 2026Femasys Partners with SandsRx Pharmacy to Support FemaSeed® Fertility Portfolio Launch to OB/GYNs
Femasys Inc. has partnered with SandsRx Pharmacy to support the launch of its FemaSeed fertility portfolio to OB/GYN practices. This collaboration aims to provide specialized pharmacy support, medication access, and pricing for patients undergoing FemaSeed treatment. The initiative is designed to integrate fertility treatments into OB/GYN practices, making care more accessible and cost-effective.
Read more →-FEMY
Oct 14, 2026▼ -11.4%on this news
Femasys Doubles Enrolling Sites in FemBloc FINALE Pivotal Trial for Non-Surgical Permanent Birth Control
Femasys Inc. has announced the doubling of actively enrolling sites in its FemBloc FINALE Pivotal Trial, now totaling twelve across the U.S. This expansion includes notable institutions like Baylor Research Institute and Columbia University Medical Center. The trial aims to evaluate FemBloc, a non-surgical permanent birth control solution, which has already received regulatory approval in Europe. The company is working towards FDA approval based on data from this pivotal study.
Read more →-FEMY
Oct 8, 2026Femasys to Exhibit at the ASRM 2026 Scientific Congress & Expo
Femasys Inc. will exhibit at the ASRM 2026 Scientific Congress & Expo from October 24-28 in Baltimore, Maryland. The company will showcase its FemaSeed Intratubal Insemination and FemVue diagnostic solutions. CEO Kathy Lee-Sepsick emphasized the importance of integrating these options into OB/GYN practices to enhance patient care. Attendees are encouraged to visit booth #513 for more information.
Read more →-FEMY
Sep 15, 2026Femasys Advances OB/GYN Expansion with Adoption of FemaSeed® Fertility Portfolio by Minnesota Women’s Care
Femasys Inc. has announced that Minnesota Women’s Care will implement its FemVue and FemaSeed fertility solutions across all four of its OB/GYN locations. This decision reflects an early recognition of the value these technologies can provide in addressing fertility needs. Femasys is also expanding its commercial team to enhance its market presence.
Read more →-FEMY
Sep 9, 2026▲ +5.6%on this news
Femasys Partners with CapexMD to Expand Patient Access to FemaSeed® Fertility Portfolio
Femasys Inc. has partnered with CapexMD to enhance patient access to its FemaSeed fertility solutions. This collaboration aims to provide financing options for patients, making fertility treatments more affordable. FemaSeed Complete is highlighted as a first-line treatment that is less costly than IVF, aiming to improve the overall fertility care experience.
Read more →-FEMY
Aug 26, 2026Femasys Partners with UNC Health to Introduce Its FemaSeed® Fertility Portfolio Across Statewide OB/GYN Care Locations
Femasys Inc. has partnered with UNC Health to offer its fertility solutions, including FemVue and FemaSeed, across OB/GYN practices in North Carolina. This collaboration aims to provide women with earlier access to fertility care and treatment options within their local communities. The initiative is expected to enhance the standard of care and reduce costs for patients.
Read more →-FEMY
Aug 19, 2026▲ +23.2%on this news
Femasys Announces FDA Approval of Modular PMA Submission Approach for FemBloc®
Femasys Inc. has received FDA approval for a modular premarket approval pathway for its FemBloc technology, a non-surgical permanent birth control solution. This approval allows for the review of key components of the submission prior to final clinical data. The company is also expanding its commercial team to support broader access to fertility care.
Read more →-FEMY
Aug 14, 2026▼ -5.7%on this news· ran to +19% by day 3shared move
Femasys Announces Financial Results for Quarter Ended June 30, 2026 and Provides Corporate Update
Femasys Inc. reported its financial results for the quarter ending June 30, 2026, highlighting a $30 million financing to bolster its commercial strategy. The company regained compliance with Nasdaq and received CE Mark approval for its FemHSG Catheter. However, it faced a decrease in sales and a net loss, although the overall financial position improved with new funding.
Read more →-FEMY
Aug 12, 2026Femasys Strengthens and Extends Global Patent Protection for FemBloc® with First Issued Blended Polymer Patents
Femasys Inc. has announced the issuance of new patents in the U.S. and internationally, enhancing the intellectual property protection for its FemBloc non-surgical permanent birth control technology. This expansion complements existing patents and strengthens FemBloc's competitive position in the market. The technology is currently approved for marketing in Europe and other select markets, while it remains investigational in the U.S.
Read more →-FEMY
Aug 7, 2026▼ -9.8%on this news· ran to -20% by day 3shared move
Femasys Secures $30 Million Private Placement, with Potential Proceeds of Up to $90 Million
Femasys Inc. has announced a $30 million private placement with accredited investors, led by Nantahala Capital. The financing, subject to customary closing conditions, is expected to close around August 10, 2026. The deal includes shares of common stock and warrants, with potential proceeds of up to $90 million upon full exercise of the warrants. This funding aims to support Femasys' growth and product commercialization efforts.
Read more →-FEMY
Jun 24, 2026▼ -8.5%on this news
Femasys Regains Compliance with Nasdaq Listing Requirements
Femasys Inc. has announced that it has regained compliance with Nasdaq's minimum bid price requirement, closing the matter. CEO Kathy Lee-Sepsick highlighted the importance of this development for shareholders and emphasized the company's commitment to advancing its reproductive health solutions. Femasys continues to focus on commercializing its innovative products in the U.S. and international markets.
Read more →-FEMY
May 13, 2026Femasys Expands Fertility Care Portfolio in Europe with CE Mark Approval for FemHSG™ Catheter
Femasys Inc. has received CE Mark approval for its FemHSG Catheter, enhancing its fertility care portfolio in Europe. This catheter, designed for in-office fertility evaluations, works in conjunction with the FemVue device. The approval aims to improve access to timely and affordable fertility diagnosis and treatment for women. CEO Kathy Lee-Sepsick emphasized the importance of expanding in-office fertility services.
Read more →-FEMY
May 13, 2026CONFIDENTAIL | NASDAQ: FEMY 1 CORPORATE PRESENTATION May 2026 2026 Femasys Inc. Redefining Women's Reproductive Health at Global Scale NASDAQ: FEMY Forward Looking Statements NASDAQ: FEMY 2 This Presentation contains "fo
Femasys Inc. is positioning itself as a leader in women's reproductive health with innovative products aimed at enhancing patient access and care. The company highlights its strong infrastructure, experienced leadership, and a promising pipeline of products, including permanent birth control options and fertility treatments. With regulatory approvals in various regions and plans for significant market expansion, Femasys aims to capture a large, underserved patient population. The presentation emphasizes the opportunities in the current healthcare landscape, particularly in light of evolving trends in women's health.
Read more →-FEMY
May 8, 2026Femasys Announces Financial Results for Quarter Ended March 31, 2026 and Provides Corporate Update
Femasys Inc. (NASDAQ: FEMY) announced its financial results for the first quarter of 2026, highlighting significant progress in its clinical and regulatory initiatives. The company is moving forward with the commercialization of its FemaSeed product family and has initiated enrollment in the FINALE pivotal clinical trial for FemBloc, a non-surgical permanent birth control solution. Despite a reported net income of $846,100 for the quarter, Femasys experienced a decrease in total assets compared to the previous quarter, coupled with rising liabilities.
Read more →-FEMY
May 5, 2026▲ +7.4%on this news· ran to +22% by day 1shared move
Femasys Enables OB/GYNs to Deliver First-Line Fertility Treatment with Initial Commercial Use of FemaSeed® Complete
Femasys Inc. has launched FemaSeed as a first-line fertility treatment in OB/GYN practices, enabling in-office sperm preparation with FemSperm. This innovation addresses the significant gap in infertility care access, allowing earlier intervention at a lower cost. The approach aims to streamline fertility treatment, improving patient outcomes and satisfaction.
Read more →-FEMY
Apr 16, 2026Femasys Drives International Growth with Israeli Market Entry for Fertility Portfolio
Femasys Inc. has entered a strategic partnership with AMI Technologies to introduce its fertility portfolio in Israel. This collaboration aims to enhance market access for innovative treatments like FemaSeed and FemVue, leveraging AMI's established infrastructure and expertise. The partnership is part of Femasys's broader strategy to expand its global footprint in women's health.
Read more →-FEMY
Apr 1, 2026Femasys Announces Financial Results for Year Ended December 31, 2025 and Provides Corporate Update
Femasys Inc. reported its financial results for the year ending December 31, 2025, highlighting significant clinical and regulatory advancements. The company is actively enrolling patients in the FINALE pivotal trial for its FemBloc product, aiming for FDA approval. Additionally, Femasys is expanding its FemaSeed commercialization efforts in the U.S. market.
Read more →-FEMY
Apr 1, 2026Femasys Appoints John Canning as Chief Operating Officer to Drive Operational Execution and Advance Commercial Growth
Femasys Inc. has appointed John Canning as Chief Operating Officer to enhance operational execution and drive commercial growth. Canning, a veteran in the medical device sector with over 25 years of experience, will leverage his skills to expand Femasys' portfolio in fertility and permanent birth control solutions. With a track record of successful leadership in prior roles, his hire is seen as pivotal for the company's strategic ambitions. The appointment is coupled with a stock option grant, signaling the company's commitment to Canning's role in its growth strategy.
Read more →-FEMY
Mar 2, 2026▼ -5.6%on this news
Femasys Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - February 27, 2026
Femasys Inc. has announced the granting of stock options to two new non-executive employees as part of their inducement grants under Nasdaq Listing Rule 5635(c)(4). The options, totaling 185,000 shares, were granted at prices reflecting the stock's closing value. This move aims to attract talent while ensuring compliance with regulatory standards.
Read more →About Femasys Inc.
Headquarters3950 JOHNS CREEK COURT, SUWANEE, GA, 30024
BIOPHARMAWATCH ELITE PLUS
Trade the next FEMY catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime